MARYKATE VELLIS: Open Payments
NPI 1720060833 · GAINESVILLE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,102 in 156 payments from 43 companies in 2025. Trend: 2023 $14,390 · 2024 $3,917 · 2025 $4,102
Food & beverage: $3,960Education: $142
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 11 | $491 |
| AstraZeneca Pharmaceuticals LP | 12 | $429 |
| Celgene Corporation | 25 | $365 |
| Janssen Biotech, Inc. | 9 | $286 |
| Gilead Sciences, Inc. | 12 | $229 |
| GENZYME CORPORATION | 7 | $197 |
| Astellas Pharma US Inc | 4 | $184 |
| Novartis Pharmaceuticals Corporation | 12 | $182 |
| Eisai Inc. | 5 | $167 |
| Boston Scientific Corporation | 1 | $152 |
Products named: REBLOZYL, Trodelvy, DATROWAY, OPDIVO, RYBREVANT, Lenvima, Enhertu, General - Interventional Oncology.
Industry payments across FL — which companies pay providers there.
